Skip to main content
← All comparisons

Best Clarivate Alternatives for Biopharma Teams in 2026

Maven Bio provides live intelligence that keeps biopharma research files current through source-linked updates.1 For example, Maven Bio maintains selected assessments as evidence changes,1 Citeline Pharmaprojects+ organizes development landscapes,2 and Evaluate supplies consensus sales forecasts for commercial research.3

Teams considering alternatives to Clarivate are often replacing a portfolio of research jobs, rather than a single database. Clarivate's life-sciences offering includes Cortellis products, OFF-X Translational Safety Intelligence, BioWorld, DRG offerings, and other named services across development and commercialization.4 This guide compares seven providers across selected parts of that scope. Clarivate is the reference portfolio, with each alternative's role stated explicitly.

The name also needs context. The former Clarivate Life Sciences & Healthcare business now identifies itself as Insira. Its current site retains Cortellis for development intelligence and DRG for commercial and market-access work.5 This guide uses Clarivate as the familiar search term and portfolio reference, while reflecting that current identity. It does not treat a change in company name as a change in every underlying product capability.

For a narrower replacement decision centered on Cortellis, see Cortellis alternatives. For the direct comparison of research workflows, see Maven Bio versus Cortellis. Here, the scope extends beyond pipeline and deal data to the broader set of life-sciences information needs.

Best Clarivate Alternatives for Biopharma Teams in 2026

Jump to a platform

How we assessed these platforms

We reviewed public product descriptions, help centers, integration documentation, and pricing pages on November 19, 2026. The comparison separates portfolio breadth from the capabilities of a named product. A feature in one module is not assumed to exist throughout a provider's portfolio. Maven Bio publishes this guide, and its own entry is held to the same evidence standard, with every claim linked to a public page.

CriterionWhat we checked
Portfolio scopeDevelopment, clinical, safety, transaction, commercial, and market-document coverage
Research evidenceStructured records, original documents, cited responses, and supporting passages
Named product boundariesWhich product supplies the capability and whether another module is involved
Working outputsResearch reports, comparison tables, exports, and maintained files
Connected accessMCP, APIs, and documented delivery into other systems
Explicit limitationsRestrictions established in help or product documentation
Prices on recordPublished prices, billing units, included capabilities, and quoted packages

The guide does not give an overall score. Portfolio breadth and workflow fit are separate considerations. A specialist source may address one research need deeply without replacing every service in an existing contract. Conversely, several datasets in one portfolio do not by themselves establish how a final research file is maintained after the underlying evidence changes.

Research tasks compared for alternatives to Clarivate

The table compares drug, trial, and company records with working-file updates and connected access. The final column concerns a provider's own consensus sales forecast dataset.

PlatformDrug, trial, and company recordsSource-linked edits to working files with rollbackMCP connectionAPI accessProvider consensus sales forecast dataset
Maven Bio9YesYesYesYesNo
Clarivate reference portfolio4YesNot describedYesYesYes
Citeline2YesNot describedNot describedYesNot described
Evaluate10YesNot describedYesYesYes
AdisInsight11YesNot describedYesYesNot described
AlphaSense7YesNot describedYesYesNot described
DealForma8YesNot describedNot describedYesNot described

Not described means the provider's public pages do not document it.

Prices on record

These public offers were checked on November 19, 2026. Dollar amounts are USD. Quote only means the reviewed page does not publish a monetary price for the named package. Portfolio names do not imply that all modules share one subscription or that every connector is included.

ProviderPublic offer on record
Maven BioQuote only for annual team plans12
Clarivate reference portfolioQuote only on the reviewed life-sciences product pages413
CitelineQuote only for Pharmaprojects+ packages2
EvaluateTailored package pricing quoted, with Ask Ella included where the subscription provides it1415
AdisInsightQuote only through the product's contact route6
AlphaSenseAnnual subscriptions, seat-based or usage-based; pricing on request7
DealForma$18,000 annually for one user, $32,000 annually for two users, and quoted group or enterprise offers for three or more users16

Maven Bio

Best for

Teams replacing fragmented research work with cited assessments and files that remain current as evidence changes.

Maven Bio provides live intelligence that monitors developments against a team's priorities and applies source-linked edits to selected Word, Excel, and PowerPoint files, with revision history and rollback.1 Research Agent supports direct answers, reviewable research plans, and finished deliverables through Answer, Plan, and Work modes, with supporting passages attached to claims.17 Teams can supply assessment criteria, project context, source preferences, and document templates, then save the method and format as a workflow that runs on demand or on a schedule.918

Smart Tables applies research columns across drugs, companies, or trials filtered by indication, mechanism, stage, and other structured fields; each cell can show supporting quotes, evidence ratings, and research steps.19 Document Grids extracts common fields across publications, abstracts, and diligence materials, including populations, endpoints, comparators, follow-up, and missing details, with supporting passages retained beside the findings.20 The read-only MCP connector supplies research access inside a compatible assistant, while the API retrieves structured biopharma data and monitoring findings and webhooks notify connected systems of new signals.9

Coverage

Maven Bio covers 100,000+ drug products, 30,000+ companies, and 11 source classes worldwide.9

Price on record

Annual team plans are quote only, with pooled AI credits and scope based on research volume, data rights, and integrations.12

Pros

Source-linked edits keep selected working files current with revision history and rollback,1 while reusable workflows retain the team's research instructions and deliverable format.18

Cons

Maven Bio does not provide its own consensus sales forecast dataset.21

Clarivate life-sciences portfolio

Best for

The reference portfolio for teams using multiple named services across development, safety, regulatory, and commercial intelligence.

Clarivate's life-sciences portfolio includes Cortellis Competitive Intelligence, Deals Intelligence, Drug Discovery Intelligence, Regulatory Intelligence, Product Intelligence, and CMC Intelligence, alongside OFF-X Translational Safety Intelligence, Drug Safety Triager, and BioWorld.4 Insira's current presentation retains Cortellis and DRG across development, commercial, and market-access research.5 Deals Intelligence provides transaction terms, available contracts, and exported financial summaries as a named component of that portfolio.13

Cortellis CCI's MCP service retrieves drug profiles, development status by indication and country, company pipelines, deals, and consensus forecasts, with links to the underlying records.22 The separate Drugs API includes active and inactive programs, chemical structures, mechanisms, indications, and development companies, with current and historical status and Word or Excel export.23 Its daily curation draws on clinical results, company releases, publications, and conference material, and late-stage or launched-drug content includes assessments of strengths, weaknesses, opportunities, and threats.23

Coverage

The Cortellis Drugs API lists 80,000+ drugs and biologics across 2,300+ diseases.23 Deals Intelligence separately lists 135,000+ transactions and 15,500+ deals with contracts.13

Price on record

The reviewed life-sciences and Cortellis product pages do not publish monetary package prices. The named offerings are quote only on those pages.413

Pros

Named products span scientific, regulatory, safety, transaction, and commercial research,4 while CCI MCP provides connected access to development records, company pipelines, deals, and consensus forecasts.22

Cons

The CCI MCP documentation does not support the ready-made Microsoft 365 Copilot Chat connector. It separately supports Claude, Copilot Studio agents, and server-to-server API access.22

Citeline

Best for

Teams replacing pipeline and clinical-research components of a broader life-sciences information stack.

Pharmaprojects+ follows development from preclinical research to launch and retains failed and withdrawn programs.2 Company Compare places active pipelines side by side, while Drug Similarity finds chemical, biologic, and mechanistic comparators.2 Search filters cover stage, modality, geography, mechanisms, and targets, and rare-disease records include orphan designations, development status, and sponsors.2 Dashboards show pipeline composition, phase progression, discontinuation patterns, and launch timelines, with annual snapshots supporting historical comparisons.2

Ella constructs and validates searches, returns structured answers from Pharmaprojects+ data, and links results to the source records.2 The assistant also works across Trialtrove+ and Sitetrove+, carrying the research context into related trial and site questions.2 Citeline's separate informatics offering provides drug, company, trial, investigator, and site data through APIs, including historical pipeline information and analytics for connected systems.24 Scheduled CSV or Parquet exports can be delivered through SFTP or cloud storage as full snapshots or daily change files, and Snowflake data shares are also available.24

Coverage

Citeline publishes 100,000+ drug profiles, 58,000+ data sources, and 40+ years of development history, with annual snapshots since 1995.2 Its stated scope includes 3,700+ mechanisms, 1,100+ targets, and 750+ rare diseases.2

Price on record

Pharmaprojects+ packages are quote only on the public product page, with the offer matched to use case and access needs.2

Pros

Failed and withdrawn programs remain available beside active assets,2 while company comparisons and drug similarity searches provide distinct ways to define a licensing landscape.2

Cons

The historical trend series is based on annual snapshots. It does not supply a snapshot for every intervening day, although current profiles are continuously updated.2

Evaluate

Best for

Teams replacing commercial forecasting and asset-assessment components of a broader research portfolio.

Evaluate Pharma combines consensus sales forecasts with product, pipeline, and company information, including worldwide and US indication-level sales coverage.3 Historical forecasts support examination of changing expectations, and the product identifies forecast outliers over time.3 Its commercial context also includes company and product deals, venture financing, IPO information, patent-expiration dates, sales at risk, and future development or regulatory events.3 Evaluate also offers Biomedtracker, which supplies drug, trial, and company data, including trial endpoints and searchable company information.10

Ask Ella answers questions from the licensed Evaluate records, links back to those sources, and retains the context of follow-up questions.15 The assistant is available within the named products supported by the subscription, rather than searching unrestricted public web material.15 Evaluate's delivery options include Snowflake, structured flat-file feeds, selected APIs, and MCP integrations; available routes depend on the dataset and intended workflow.25 Flat-file delivery supports CSV and XML, with format availability depending on the dataset and delivery requirements.25

Coverage

Evaluate Pharma lists forecasts for almost 6,000 drugs, indication-level worldwide sales for 5,000 drugs, and US indication sales for 2,500 drugs.3 Its historical collection includes 1.5 million+ consensus forecasts for 10,000 products dating to 2003.3

Price on record

Evaluate quotes packages based on the organization's data and workflow needs. Ask Ella is included where the existing subscription provides it.1415

Pros

Consensus forecasts supply a defined commercial reference for asset research,3 while Ask Ella links its answers to the licensed records supporting each response.15

Cons

Ask Ella uses licensed Evaluate records and does not search the web. Research into public developments outside those records follows a separate path.15

AdisInsight

Best for

Drug development, clinical-trial, and safety research grounded in curated scientific profiles.

AdisInsight combines drug development, clinical trials, deals, patents, and safety information in human-reviewed profiles, with AskAdis for conversational research and dashboards for indication-level analysis.6 Its public delivery options include XML feeds and APIs.6 MCP searches add structured retrieval over drugs, trials, phase changes, study-status changes, timelines, and safety reports, with access to supporting narratives, related profile tables, and original source XML.11

Drug searches can combine disease, phase, company, mechanism, target, route, formulation, country, designation, and date, while trial searches add study status and results.11 Drug timelines retain milestones by disease and can distinguish development lines by country, route, formulation, and patient segment.11 Trial timelines return the current status and the chronological sequence of earlier changes, separately from drug-phase histories.11 Related drug tables include organization records, while company searches rank drug developers and trial sponsors.11 Related tables can be retrieved in pages with totals, and the knowledge-base operation explains dataset fields, matching behavior, and relationships between records.11

Coverage

AdisInsight's MCP documentation identifies approximately 347,000 safety reports, including literature case reports of adverse reactions and other safety reporting.11

Price on record

The public product page directs organizations to a contact route and does not publish a monetary subscription price. AdisInsight is quote only on that page.6

Pros

Drug and trial timelines preserve different development histories,11 while curated profiles and safety reports provide additional scientific evidence through the same connected research service.611

Cons

The MCP chart function groups records by one or two fields. More complex multidimensional charting requires work beyond that documented chart function.11

AlphaSense

Best for

Teams replacing or adding market-document research, broker content, and company-focused analysis.

AlphaSense combines company documents, broker and independent research, expert transcripts, news, and regulatory content in its research environment.7 SuperAnalyst, currently in beta, creates cited reports, presentations, spreadsheets, financial models, dashboards, watchlists, and research memos; it can revise existing deliverables using new data.26 Project history, instructions, and earlier work persist across sessions, and users can follow the cited sources and redirect the investigation while a task is underway.26

Reusable Skills preserve a multi-step assignment, including a team's processes and templates, and scheduled automations can produce new artifacts or update existing ones.26 The guide distinguishes those Skills from Generative Search's saved single-prompt workflows and describes stepwise slide editing and use of the team's own presentation template.26 A separate clinical-trial and drug-data beta adds structured development research, with search, filters, saved views, CSV exports, and links into drug and trial profiles; the documentation identifies citation links to some profile sections as still being refined.27

Coverage

AlphaSense publishes coverage of more than 500 million documents and broker or independent research from 1,000+ firms.7

Price on record

Annual subscriptions, seat-based or usage-based; pricing on request.7

Pros

Premium market content broadens company research beyond public disclosures,7 while reusable Skills and scheduled artifact updates carry cited findings into reports, spreadsheets, and presentations.26

Cons

The SuperAnalyst automation guide lists event-reactive triggers as forthcoming. The currently documented recurring automation operates on schedules.26

DealForma

Best for

Teams replacing the transaction and financing research component of a broader intelligence portfolio.

DealForma connects deal, funding, company, and pipeline research, including financial terms, detailed transaction overviews, contracts, and supporting releases.8 The deal taxonomy covers licensing, R&D collaborations, academic agreements, M&A, spin-outs, and asset purchases, with fields for development stage, modality, indication, target, and territory.8 Funding coverage includes venture rounds, IPOs, follow-on offerings, investor histories, and financing details, while company profiles extend across biotech, pharma, diagnostics, medtech, digital therapeutics, and investment firms.8

The pipeline and sales collection includes early-stage compounds, platforms, branded drugs, labels, drug sales, launches, clinical trials, regulatory information, routes, dosages, and formulations.8 Natural-language search works alongside detailed filters, and common identifiers support connections to the team's other datasets.8 Tableau dashboards provide filtered views by therapy area, modality, stage, and other criteria; chart images and underlying data can be downloaded, and those dashboards refresh daily.28 The platform also describes API delivery into internal dashboards and exports for further analysis.8

Coverage

The published scope spans four collections, deals, funding, companies, and drug pipelines with sales data, with company coverage described as thousands of biopharma organizations.8

Price on record

DealForma lists $18,000 annually for one user and $32,000 annually for two users. Group and enterprise access for three or more users is quoted.16

Pros

Transaction and financing records connect deal terms with company activity,8 while filtered Tableau dashboards provide downloadable charts and data for further analysis and presentations.28

Cons

Tableau dashboards refresh daily, so their charts do not provide a continuously refreshed intraday view of transaction activity.28

How to choose alternatives to Clarivate

Begin with the named products and the decisions they support. A contract covering pipeline research, safety, and market-access work contains several distinct requirements. The replacement question becomes clearer when each requirement is attached to an actual work product, such as a development landscape, a safety evidence review, a commercial assessment, or a partnering presentation. Brand-level comparisons are too broad to resolve those differences on their own.

Then separate the evidence source from the research workflow. A team can retain a specialist dataset while changing how it produces and maintains its assessments. Maven Bio's live intelligence connects new evidence to selected working files,1 while the other entries address particular database, forecast, document, or transaction needs. A complete replacement and a complementary research layer are different outcomes, and the relevant scope follows the work being changed.

Finally, keep the product boundaries visible during the evaluation. A capability in one module does not establish availability across every subscription, connector, or dataset from that provider. The comparison should preserve the named product, source collection, and output format at each step. That produces a more useful decision than asking whether one provider is universally broader, because it shows which research jobs are covered and where a separate source or process remains necessary.

Frequently asked questions

What are the main alternatives to Clarivate for biopharma teams?

Maven Bio provides cited research and source-linked updates to selected working files.1 Citeline addresses development and clinical research, Evaluate supplies commercial forecasts, AdisInsight covers scientific development and safety evidence, AlphaSense provides market-document research, and DealForma focuses on deals and financing. The relevant alternative follows the component being replaced, rather than a claim that every provider covers the entire reference portfolio.

Is Clarivate Life Sciences & Healthcare now called Insira?

Yes. The site states “Insira is formerly Clarivate Life Sciences & Healthcare” and retains Cortellis and DRG in its portfolio presentation.5 The familiar product names remain useful when defining the research requirement. A portfolio review can acknowledge the current business identity while comparing the named products and workflows that the team actually uses.

How is this different from choosing a Cortellis alternative?

Cortellis is one part of the broader reference portfolio. The life-sciences pages also identify OFF-X, BioWorld, DRG-related offerings, and other services.4 A Cortellis-focused comparison can center on development and related intelligence. A portfolio-level assessment also considers which safety, commercial, regulatory, or other specialist needs are included in the replacement scope.

Can one platform replace every service in a portfolio contract?

The public documentation reviewed here establishes specific capabilities for named products. It does not establish that any one alternative is a complete substitute for every service in a multi-product contract. The practical unit of comparison is the research job and its evidence requirement. Several jobs can share a research workflow while still depending on different specialist source collections.

Does access through an AI assistant replace the underlying database?

An assistant changes the way a question reaches the data. It does not make every connected source equivalent. Maven Bio, Cortellis CCI, and AdisInsight document their own connected research routes,221129 but the underlying records and outputs retain their product-specific scope. The source collection remains part of the assessment even when the visible interface is the same assistant.

How can a team keep its final assessment current?

Maven Bio applies source-linked edits to selected working files and retains revision history and rollback.1 Its reusable workflows preserve research instructions, source preferences, and deliverable formats for scheduled work.18 AlphaSense SuperAnalyst also documents scheduled artifact updates.26 These are specific maintenance capabilities to evaluate alongside the source collection and research outputs.